Targeting the kynurenine pathway-related alterations in alzheimer's disease: A future therapeutic strategy

Journal of Alzheimer's Disease

Volumn 24, Issue SUPPL. 2, 2011, Pages 199-209

  Plangár, Imola ^a   Zádori, Dénes ^a   Klivényi, Péter ^a   Toldi, József ^b   Vécsei, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Alzheimer's disease; animal models; kynurenine pathway; therapy

Indexed keywords

4 CHLOROKYNURENINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GLUTAMIC ACID; KYNURENIC ACID DERIVATIVE; KYNURENINE; MEMANTINE; RIVASTIGMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DRUG ACTIVITY; DRUG TARGETING; EXCITOTOXICITY; HUMAN; IN VIVO STUDY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 79955643831     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-110131     Document Type: Review

References (113)

1. Murman DL, Chen MS, Powell MC, Kuo SB, Bradley CJ, Colenda CC (2002) The incremental direct costs associated with behavioralsymptoms in AD. Neurology 59, 1721-1729. (Pubitemid 35424453)
2. Gauthier S, Loft H, Cummings J (2007) Improvement in behavioural symptoms in patients with moderate to severe AD by memantine: a pooled data analysis. Int J Geriatr Psychiatry 23, 537-545.
3. Davies P (1979) Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 171, 319-327. (Pubitemid 10246672)
4. Mann DMA, Yates PO (1986) Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. Hum Neurobiol5, 147-158.
5. Hyman BT, Kromer LJ, Van Hoesen GW (1987) Rein-nervation of the hippocampal perforant pathway zone in Alzheimer's disease. Ann Neurol 21, 259-267. (Pubitemid 17035282)
6. Lassmann H, Fischer P, Jellinger K (1993) Synaptic path-ology of Alzheimer's disease. Ann N Y Acad Sci 695, 59-64.
7. Heffernan JM, Eastwood SL, Nagy S, Sanders MW, McDonald B, Harrison PJ (1998) Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia. Exp Neurol 150, 235-239. (Pubitemid 28231954)
8. Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, Wilson JM, DiStefano LM, Nobrega JN (1992) Brain cytochrome oxidase in Alzheimer's disease. J Neu-rochem 59, 776-779.
9. Lambert JC, Wavrant-De Vrieze F, Amouyel P, Chartier-Harlin MC (1998) Association at LRP gene locus with sporadic late-onset Alzheimer's disease. Lancet 351, 1787-1788. (Pubitemid 28269197)
10. Shin J, Yu SB, Yu UY, Jo SA, Ahn JH (2010) Swedish mutation within amyloid precursor protein modulates global gene expression towards the pathogenesis of Alzheimer's disease. BMB Rep 43, 704-709.
11. Selkoe DJ, American College of Physicians, American Physiological Society (2004) Alzheimer disease: mechanis-tic understanding predicts novel therapies. Ann Intern Med 140, 627-638.
12. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A (2006) Opposing activities protect against age-onset pro-teotoxicity. Science 313, 1604-1610. (Pubitemid 44414028)
13. Hardy J, Crook R (2001) Presenilin mutations line up along transmembrane alpha-helices. Neurosci Lett 306, 203-205. (Pubitemid 32530834)
14. Coleman P, Kurlan R, Crook R, Werner J, Hardy J (2004) A new presenilin Alzheimer's disease case confirms the heli-cal alignment of pathogenic mutations in transmembrane domain 5. Neurosci Lett 364, 139-140. (Pubitemid 38757919)
15. Kidd M (1963) Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 197, 192-193.
16. Matsumura N, Yamazaki T, Ihara Y (1999) Stable expres-sion in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome-17 (FTDP-17). Am J Pathol 154, 1649-1656. (Pubitemid 29262846)
17. Perez M, Lim F, Arrasate M, Avila J (2000) The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules. J Neurochem 74, 2583-2589. (Pubitemid 30314236)
18. Sahara N, Tomiyama T, Mori H (2000) Missense point muta-tions oftau to segregate with FTDP-17 exhibit site-specific effects on microtubule structure in COS cells: a novel action ofR406W mutation. J Neurosci Res 60, 380-387. (Pubitemid 30253602)
19. Connell JW, Gibb GM, Betts JC, Blackstock WP, Gallo JM, Lovestone S, Hutton M, Anderton BH (2001) Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3β identified by mass spec-trometry demonstrate certain mutations exert long-range conformational changes. FEBS Lett 493, 40-44. (Pubitemid 32241173)
20. Peng W, Cotrina ML, Han X, Yu H, Bekar L, Blum L, Takano T, Tian GF, Goldman SA, Nedergaard M (2009) Systemic administration of an antagonist of the ATP-sensiti ve receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci US A 106, 12489-12493.
21. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, La erla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421. (Pubitemid 36937044)
22. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM, (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging24, 1063-1070. (Pubitemid 37487883)
23. Baumeister R, Leimer U, Zweckbronner I, Jakubek C, Grunberg J, Haass C (1997) Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing. Genes Funct 1, 149-159.
24. Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92, 9368-9372.
25. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, Gubb DC, Lomas DA (2005) Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 132, 123-135. (Pubitemid 40380720)
26. Bharadwaj P, Waddington L, Varghese J, Macreadie IG (2008) A new method to measure cellular toxicity of non-fibrillar and fibrillar Alzheimer's Abeta using yeast. J Alzheimers Dis 13, 147-150. (Pubitemid 352038519)
27. Giorgini F, Guidetti P, Nguyen QV, Bennett SC, Muchowski PJ (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington's disease. Nat Genet 37, 526-531. (Pubitemid 40617282)
28. Giorgini F, Möller T, Kwan W, Zwilling D, Wacker JL, Hong S, Tsai LCL, Cheah CS, Schwarcz R, Guidetti P, Muchowski PJ (2008) Histone deacetylase inhibition modu-lates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem 283, 7390-7400.
29. Newman M, Verdile G, Martins RN, Lardelli M (2011) Zebrafish as a tool in Alzheimer's disease research. Biochim Biophys Acta 1812, 346-352.
30. Paquet D, Bhat R, Sydow A, Mandelkow EM, Berg S, Hellberg S, Falting J, Distel M, Koster RW, Schmid B, Haass C (2009) A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest119, 1382-1395.
31. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112. (Pubitemid 46432529)
32. Boumezbeur F, Mason GF, de Graaf RA, Behar KL, Cline GW, Shulman GI, Rothman DL, Petersen KF (2010) Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J Cereb Blood Flow Metab 30, 211-221.
33. Yang JL, Weissman L, Bohr VA, Mattson MP (2008) Mito-chondrial DNA damage and repair in neurodegenerative disorders. DNA Repair 7, 1110-1120.
34. Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P, Rizzuto R (2009) Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Biochim Biophys Acta 1787, 335-344.
35. Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X (2009) The role of abnormal mitochondrial dynamics in the patho-genesis of Alzheimer's disease. JNeurochem 109, 153-159.
36. Du H, Yan SS (2010) Mitochondrial permeability transition porein Alzheimer's disease: cyclophilin D and amyloidbeta. Biochim Biophys Acta 1802, 2-10.
37. Wang X, Su B, Perry G, Smith MA, Zhu X (2007) Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer's disease. Free Radic Biol Med 43, 1569-1573. (Pubitemid 350122990)
38. De Vos KJ, Grierson AJ, Ackerley S, Miller CC (2008) Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci31, 151-173.
39. Keller JN, Guo Q, Holtsberg FW, Bruce-Keller AJ, Mattson MP (1998) Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. JNeurosci 18, 4439-4450. (Pubitemid 28280155)
40. Yu JT, Chang RC, Tan L (2009) Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog Neurobiol 89, 240-255.
41. Olney JW (1969) Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164, 719-721.
42. Doble A (1999) The role of excitotoxicity in neurodegenerative disease: implications oftherapy. Pharmacol Ther 81, 163-221. (Pubitemid 29094735)
43. Schousboe A, Waagepetersen HS (2005) Role of astrocytes in glutamate homeostasis: implications for excitotoxicity. Neurotox Res 8, 221-225.
44. Hugon J, Vallat JM, Dumas M (1996) Role of glutamate and excitotoxicity in neurologic diseases. Rev Neurol (Paris) 152, 239-248. (Pubitemid 26189439)
45. Rao AV, Balachandran B (2002) Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci 5, 291-309. (Pubitemid 35174629)
46. Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischaemic neuronal death. Annu Rev Neurosci13, 171-182. (Pubitemid 20100647)
47. Longoni M, Ferrarese C (2006) Inflammation and excitotoxicity: role in migraine pathogenesis. Neurol Sci 27, 107-110.
48. Koutsilieri E, Riederer P (2007) Excitotoxicity and new antiglutamatergic strategies in PD and AD. Parkinsonism Relat Disord 13, 329-331.
49. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate and neurodegenerative disorders. Science 262, 689-695. (Pubitemid 23350687)
50. Parameshwaran K, Dhanasekaran M, Suppiramaniam V (2008) Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol 210, 7-13. (Pubitemid 351258072)
51. Greenamyre JT, Young AB (1989) Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 10, 593-602. (Pubitemid 19245482)
52. Liévens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, Bates GP (2001) Impaired glutamate uptake in the R6 HD transgenic mice. Neurobiol Dis8, 807-821. (Pubitemid 33055597)
53. Muir KW (2006) Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 6, 53-60. (Pubitemid 43103819)
54. Schwarcz R (2004) The kynurenine pathway of tryptophan degradationas adrug target. Curr Opin Pharmacol 4, 12-17. (Pubitemid 38145832)
55. Fülöp F, Szatmári I, Vámos E, Zádori D, Toldi J, Vécsei L (2009) Synthesis, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 16, 4828-4842.
56. Borza I, Kolok S, Galgóczy K, Gere A, Horváth C, Farkas S, Greiner I, Domány G (2007) Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett 17, 406-409. (Pubitemid 46073751)
57. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and metaanalysis. Clin Interv Aging 3, 211-225. (Pubitemid 352037861)
58. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, Akaike A (2003) Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 306, 772-777. (Pubitemid 36886179)
59. Akasofu S, Kimura M, Kosasa T, Sawada K, Ogura H (2008) Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. Chem Biol Interact 175, 222-226.
60. Wang D, Noda Y, Zhou Y, Mouri A, Mizoguchi H, Nitta A, Chen W, Nabeshima T (2007) The allosteric potentiation of nicotinic acetylcholinereceptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32, 1261-1271. (Pubitemid 46788859)
61. Loy C, Schneider L (2006) Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 1, CD001747.
62. Venneri A, McGeown WJ, Shanks MF (2005) Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport 16, 107-110. (Pubitemid 40250379)
63. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R (2005) Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 59, 473-477. (Pubitemid 40467894)
64. Parsons CG, Danysz W, Quack G (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review ofpreclinical data. Neuropharmacology 38, 735-767. (Pubitemid 29187336)
65. McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev 19, CD003154.
66. Chohan MO, Khatoon S, Iqbal I-G, Iqbal K (2006) Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by memantine. FEBS Lett 580, 3973-3979. (Pubitemid 43946883)
67. Gunnarsson MD, Kilander L, Sudelöf J, Basun H, Lannfelt L (2006) O3-05-07: Reduction of hyperphosphorylatedtau during memantine treatment of Alzheimer's disease. Alzheimers Dement 2(3 Suppl), S63-S64.
68. Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M (2010) Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol 17, 405-412.
69. Vécsei L (ed.) (2005) Kynurenines in the Brain. From Experiments to Clinics, Nova, New York.
70. Robotka H, Toldi J, Vécsei L (2008a) L-Kynurenine: metabolism and mechanism of neuroprotection. Future Neurol 3, 169-188. (Pubitemid 351385961)
71. Németh H, Toldi J, Vécsei L (2006) Kynurenines, PD and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm 70, 285-304. (Pubitemid 44622214)
72. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith OR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56, 2007-2017.
73. Gal EM, Sherman AD (1978) Synthesis and metabolism of L-kynurenine in rat brain. J Neurochem 30, 607-613. (Pubitemid 8291438)
74. Stone TW, Connick JH (1985) Quinolinic acid and other kynurenines in the central nervous system. Neuroscience 15, 597-617. (Pubitemid 15236335)
75. Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52, 1319-1328. (Pubitemid 19085960)
76. Perkins MN, Stone TW (1985) Actions of kynurenic acid and quinolinic acid in the rat hippocampus in vivo. Exp Neurol 88, 570-579. (Pubitemid 15027225)
77. Prescott C, Weeks AM, Staley KJ, Partin KM (2006) Kynurenic acid has a dual action on AMPA receptor re-sponses. Neurosci Lett 402, 108-112. (Pubitemid 43766458)
78. RózsaÉ, Robotka H, Vécsei L, Toldi J (2008) The Janus-face kynurenic acid. J Neural Transm 115, 1087-1091.
79. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: phys-iopathological implications. J Neurosci 21, 7463-7473. (Pubitemid 32904945)
80. Pereira EF, Hilmas C, Santos MD, Alkondon M, Maelicke A, Albuquerque EX (2002) Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 53, 479-500. (Pubitemid 35375580)
81. Alkondon M, Pereira EF, Yu P, Arruda EZ, Almeida LE, Guidetti P, Fawcett WP, Sapko MT, Randall WR, Schwarcz R, Tagle DA, Albuquerque EX (2004) Targeted deletion of the kynurenine aminotransferase ii gene reveals a crit-ical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha 7 nicotinic receptors in the hippocampus. J Neurosci 24, 4635-4648. (Pubitemid 38656619)
82. Vécsei L, Beal MF (1990) Intracerebroventricular injec-tion of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behaviour in rats. Brain Res Bull 25, 623-627.
83. Chess AC, Simoni MK, Alling TE, Bucci DJ (2007) Eleva-tions of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 33, 797-804. (Pubitemid 47343705)
84. Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, Schwarcz R (2010) Reduction of endogenous kynurenic acid formation enhances extra-cellular glutamate, hippocampal plasticity, and cognitive behaviour. Neuropsychopharmacology 35, 1734-1742.
85. Stone TW, Perkins MN (1981) Quinolic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol72, 411-412. (Pubitemid 11081065)
86. de Carvalho LP, Bochet P, Rossier J (1996) The endoge-nous agonist quinolinic acid and the non endogenous homo-quinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int 28, 445-452. (Pubitemid 26120215)
87. 3H] Homoquinolinate binds to a subpopulation of NMDA receptors and to a novel binding site. JNeurochem 71, 1464-1470. (Pubitemid 28443018)
88. Rios C, Santamaria A (1991) Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 16, 1139-1143.
89. Santamaria A, Galván-Arzate S, Lisy V, Ali SF, Duhart HM, Osorio-Rico L, Rios C, St'Astny F (2001) Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neurore-port12, 871-874. (Pubitemid 32222733)
90. Guillemin GJ, Croitoru-Lamoury J, Dormont D, Armati PJ, Brew BJ (2003) Quinolinic acid upregulates chemokine pro-duction and chemokine receptor expression in astrocytes. Glia 41, 371-381. (Pubitemid 36314150)
91. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ (2009) Mechanism for quinolinic acid cytotoxicity in human astro-cytes and neurons. Neurotox Res 16, 77-86.
92. Ting KK, Brew BJ, Guillemin GJ (2009) Effect of quino-linic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation 10, 6-36.
93. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM (2005) Indoleamine 2, 3-dioxygenase and quinolinic acid immunoreactivity in Alzheimer' disease hippocampus. Neuropathol Appl Neurobiol 31, 395-404. (Pubitemid 41059860)
94. Rogers J, Shen Y (2000) A perspective on inflammation in Alzheimer's disease. Ann N Y Acad Sci 924, 132-135. (Pubitemid 32050194)
95. Guillemin GJ, Smythe GA, Veas LA, Takikawa O, Brew BJ (2003b) A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 14, 2311-2315.
96. Stone TW, Behan WM, Jones PA, Darlington LG, Smith RA (2001) The role of kynurenines in the production of neuronal death, and the neuroprotective effect of purines. J Alzheimers Dis 3, 355-366. (Pubitemid 32843052)
97. Okuda S, Nishiyama N, Saito H, Katsuki H (1996) Hydro-gen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin 3-hydroxykynurenine. Proc Natl Acad Sci USA 93, 12553-12558. (Pubitemid 26367182)
98. Bonda DJ, Mailankot M, Stone JG, Garrett MR, Stanis-zewska M, Castellani RJ, Siedlak SL, Zhu X, Lee HG, Perry G, Nagaraj RH, Smith MA (2010) Indoleamine 2, 3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of AD. Redox Rep 15, 161-168.
99. Sas K, Robotka H, Rózsa É, Agoston M, Szénási G, Gigler G, Marosi M, Kis Z, Farkas T, Vécsei L, Toldi J (2008) Kynurenine diminishes the ischaemia induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol Dis 32, 302-308.
100. Schwarcz R, Pellicciari R (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther303, 1-10.
101. Smith DH, Okiyama K, Thomas MJ, Mcintosh TK (1993) Effects of excitatory amino acid receptor antagonists kynurenate and indole-2-carboxylic acid on behavioural and neurochemical outcome following experimental brain injury. JNeurosci 13, 5383-5392. (Pubitemid 24001020)
102. Luchowska E, Luchowski P, Sarnowska A, Wielosz M, Turski WA, Urbanska EM (2003) Endogenous level of kynurenic acid and activities of kynurenine aminotrans-ferases following transient global ischaemia in the gerbil hippocampus. Pol J Pharmacol 55, 443-447. (Pubitemid 36975212)
103. Gigler G, Szénási G, Simó A, Lévay G, Hársing LG Jr, Sas K, Vécsei L, Toldi J (2007) Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischaemia in mice and global cerebral ischaemia in gerbils. Eur JPharmacol 564, 116-122. (Pubitemid 46946855)
104. Hokari M, Wu HQ, Schwarcz R, Smith QR (1996) Facili-tated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid. Neuroreport 8, 15-18. (Pubitemid 126785523)
105. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K (2004) Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neu-rodegeneration. FEBS Lett 566, 261-269. (Pubitemid 38625969)
106. Lee SC, Schwarcz R (2001) Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striatum in vivo. Neurosci Lett 304, 185-188. (Pubitemid 32436407)
107. Wu HQ, Lee SC, Schwarcz R (2000) Systemic administra-tion of 4-chlorokynurenine prevents quinolinate neurotoxi-city in the rat hippocampus. Eur J Pharmacol 390, 267-274. (Pubitemid 30119941)
108. Parli CJ, Krieter P, Schmidt B (1980) Metabolism of 6-chlorotryptophan to 4-chloro-3-hydroxyanthranilic acid: a potent inhibitor of 3-hydroxyanthranilic acid oxidase. Arch Biochem Biophys 203, 161-166. (Pubitemid 11147994)
109. Kiss C, Vécsei L (2009) Kynurenines in the brain: pre-clinical and clinical studies, therapeutic considerations. In Handbook ofNeurochemistry and Molecular Neurobiology, Lajtha A, ed. 3rd edn. Brain and Spinal Cord Trauma, Springer-Verlag, Berlin, Heidelberg, pp. 91-105.
110. Röver S, Cesura AM, Huguenin P, Kettler R, Szente A (1997) Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl) benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 40, 4378-4385. (Pubitemid 28042317)
111. Fitzgerald DH, Muirhead KM, Botting NP (2001) A comparative study on the inhibition of human and bacte-rial kynureninase by novel bicyclic kynurenine analogues. Bioorg Med Chem 9, 983-989. (Pubitemid 32448118)
112. Walsh HA, Leslie PL, O'Shea KC, Botting NP (2002) 2-Amino-4-[3- hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor ofrat and recombinant human kynureninase. Bioorg Med Chem Lett 12, 361-363. (Pubitemid 34113903)
113. Zádori D, Klivényi P, Plangár I, Toldi J, Vécsei L (2010) Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol, (inpress). doi:10.1111/j.1582-4934.2010.01237.x